ULTRAVATE: payments to doctors
Payments that named ULTRAVATE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $272K
- Providers
- 3,190
- Transactions
- 9,208
- Average per transaction
- $30
The per-transaction average — $30 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 3,190 providers the average total is $85, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| SUN Pharmaceutical Industries Inc. | $159,168 | 58.6% |
| Sun Pharmaceutical Industries Inc. | $101,348 | 37.3% |
| TARO Pharmaceuticals USA, Inc. | $11,201 | 4.1% |